Abstract

The aim: To substantiate, develop and apply in clinical practice a method for the treatment of combined acne and genitourinary infections caused by chlamydia and mycoplasmas. Materials and methods: Acne was diagnosed clinically. Chlamydia trachomatis; Mycoplasma genitalium; Mycoplasma hominis; Ureaplasma urealyticum were identified using polymerase chain reaction. 30 patients with combined acne and urogenital chlamydia and/or mycoplasmas received sequential oral antibiotic therapy with josamycin (1500 mg daily) and gatifloxacin (400 mg daily) for 10 days each. Simultaneously with antibiotic therapy, concomitant symptomatic and topical treatment was provided. Results: The elimination of pathogens of urogenital chlamydia and/or mycoplasmas was achieved with 29 out of 30 patients (93.3%). At the same time a complete regression of facial rash inflammatory elements was detected at 18 (60%) treated patients, while with the remaining 12 (40%) the regression was significant. Conclusions: Antibiotic therapy was used in the treatment for both acne and urogenital chlamydia and/or mycoplasmas. An original method of complex treatment of combined acne and urogenital chlamydia and/or mycoplasmas was substantiated, developed and successfully applied. The offered method of treatment can be considered as a proof of high effectiveness both for elimination of pathogens from the genitourinary system of patients, and for complete or significant elimination of inflammatory facial rash.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.